Incyte Acquires Vega Therapeutics to Expand Hematology Portfolio in Bleeding Disorders

Incyte has entered into a definitive agreement to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, for $1.25 billion upfront, with up to $750 million in additional milestone payments for total potential consideration of up to $2.0 billion. The deal is intended to add Vega’s Phase 3 monoclonal antibody candidate VGA039 for von Willebrand disease to Incyte’s hematology portfolio.